EUCTR2008-006773-32-GB
Active, not recruiting
Phase 1
A Phase IV, randomised study to evaluate the immune responses of UK adolescent girls receiving Cervarix(TM) or Gardasil(TM) Human Papillomavirus vaccines - RCT of immune response in UK adolescent girls to HPV vaccines
ConditionsThis study will investigate vaccines that prevent premalignant cervical lesions and cervical cancer causally related to Human Papillomavirus (HPV) types 16 and 18. This study will investigate whether immunisation against infection with HPV 16 and 18 may impact on other oncogenic HPV types, through cross-protection.MedDRA version: 9.1 Level: LLT Classification code 10058580 Term: Human papilloma virus serology test
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- This study will investigate vaccines that prevent premalignant cervical lesions and cervical cancer causally related to Human Papillomavirus (HPV) types 16 and 18. This study will investigate whether immunisation against infection with HPV 16 and 18 may impact on other oncogenic HPV types, through cross-protection.
- Sponsor
- Health Protection Agency
- Enrollment
- 84
- Status
- Active, not recruiting
- Last Updated
- 7 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Aged between 13 and 15 years at the time of the first immunisation
- •No contraindications to vaccination as specified in the Green Book” – Immunisation Against Infectious Disease, HMSO.
- •Written informed consent obtained from parent or guardian of subject
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) no
- •F.1\.2\.1 Number of subjects for this age range
- •F.1\.3 Elderly (\>\=65 years) no
- •F.1\.3\.1 Number of subjects for this age range
Exclusion Criteria
- •Pregnant or become pregnant during the course of the trial (no contraindications to vaccination for those taking the contraceptive pill).
- •Allergic to vaccine components
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
A Phase IV, randomised study to evaluate the immune response of UK infants receiving DTaP/Hib/IPV, meningococcal C conjugate and pneumococcal conjugate vaccines, antibody persistence and responses to booster doses in the second year of life. (code: Sched2) - Sched2All products arre vaccines and are given to healthy volunteers to induce immunological responses to provide protection against:Pediacel - tetanus, diphtheria, polio, pertussis (whooping cough), Haemophilus influenza ttype b (Hib disease)Menjugate and Nies-VacC - meningococcal C diseasePrevenar - pneumococcal diseaseMedDRA version: 9.1Level: PTClassification code 10027274Term: Meningococcal infectionMedDRA version: 9.1Level: LLTClassification code 10061353Term: Pneumococcal infectionMedDRA version: 9.1Level: LLTClassification code 10013023Term: DiphtheriaMedDRA version: 9.1Level: LLTClassification code 10043376Term: TetanusMedDRA version: 9.1Level: LLTClassification code 10034738Term: PertussisMedDRA version: 9.1Level: LLTClassification code 10018955Term: Haemophilus meningitisMedDRA version: 9.1Level: LLTClassification code 10036008Term: PolioEUCTR2007-004056-36-GBHealth Protection Agency
Active, not recruiting
Not Applicable
Study on the evaluation of the short-term and long-term response to the anti-flu vaccination Inflexal V in elderly patientsEUCTR2011-003188-31-ITCRUCELL SWITZERLAND AG
Active, not recruiting
Not Applicable
Open Phase IV Clinical Study to Evaluate the Immunogenicity and Safety of a Rapid Immunization Schedule with FSME-IMMUN 0.25ml JUNIOR in Healthy Children aged 1 to below 15 Years - Pediatric Rapid TBE Immunization StudyEvaluation of Immunogenicity of a TBE (Tick Borne Encephalitis) Vaccine in previously unvaccinated children aged 1 to below 15 yearsMedDRA version: 12.1Level: LLTClassification code 10043847Term: Tick-borne viral encephalitisEUCTR2010-020097-42-ATBaxter Innovations GmbH240
Active, not recruiting
Phase 1
Open Phase IV Clinical Study to Evaluate the Immunogenicity and Safety of a Rapid Immunization Schedule with FSME-IMMUN 0.25 ml JUNIOR in Healthy Children aged 3 - 15 YearsPrevention of Tick-born encephalitis (TBE). The rapid immunization schedule recommended in the current SPC for FSME-IMMUN 0.5 ml (Day 0, Day 14) has been used in Austria for 20 years. FSME-IMMUN 0.25 ml was first administered in clinical trials in the year 2001 and the rapid immunization schedule is recommended for children ranging 1 to 16 years of age. However, limited data on immunogenicity when using the rapid immunization schedule in children exist.MedDRA version: 9.1Level: LLTClassification code 10043847Term: Tick-borne viral encephalitisEUCTR2007-000810-35-CZBIOVOMED300
Completed
Phase 4
to evaluate the Immunogenicity and Safety of Typbar-TCV® in AdultsCTRI/2019/10/021823Bharat Biotech International Ltd300